News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
235,567 Results
Type
Article (13303)
Company Profile (22)
Press Release (222242)
Section
Business (71344)
Career Advice (1113)
Deals (14427)
Drug Delivery (39)
Drug Development (34499)
Employer Resources (47)
FDA (6587)
Job Trends (5781)
News (125243)
Policy (10315)
Tag
2024 Biotech Bay Standard (3)
2024 Genetown Standard (1)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (1)
Academia (760)
Adcomms (7)
Allergies (46)
Alliances (11158)
ALS (40)
Alzheimer's disease (530)
Antibody-drug conjugate (ADC) (60)
Approvals (6649)
Artificial intelligence (111)
Autoimmune disease (10)
Automation (7)
Bankruptcy (110)
Best Places to Work (4936)
BIOSECURE Act (4)
Biosimilars (62)
Biotechnology (20)
Bladder cancer (51)
Brain cancer (19)
Breast cancer (168)
Cancer (1249)
Cardiovascular disease (88)
Career advice (882)
Career pathing (8)
CAR-T (58)
Cell therapy (183)
Cervical cancer (13)
Clinical research (29736)
Collaboration (395)
Compensation (188)
Complete response letters (2)
COVID-19 (999)
CRISPR (15)
C-suite (67)
Cystic fibrosis (36)
Data (1295)
Depression (19)
Diabetes (136)
Diagnostics (2280)
Digital health (5)
Diversity, equity & inclusion (13)
Drug discovery (54)
Drug pricing (36)
Drug shortages (11)
Duchenne muscular dystrophy (53)
Earnings (50327)
Editorial (14)
Employer branding (10)
Employer resources (43)
Events (33043)
Executive appointments (284)
FDA (7202)
Featured Employer (10)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (4)
Funding (393)
Gene editing (48)
Generative AI (8)
Gene therapy (131)
GLP-1 (412)
Government (1509)
Grass and pollen (3)
Guidances (36)
Healthcare (6823)
Huntington's disease (10)
IgA nephropathy (15)
Immunology and inflammation (52)
Indications (15)
Infectious disease (1079)
Inflammatory bowel disease (52)
Inflation Reduction Act (3)
Influenza (39)
Intellectual property (35)
Interviews (194)
IPO (8431)
IRA (11)
Job creations (1177)
Job search strategy (771)
Kidney cancer (9)
Labor market (16)
Layoffs (158)
Leadership (5)
Legal (2094)
Liver cancer (38)
Lung cancer (208)
Lymphoma (94)
Machine learning (2)
Management (11)
Manufacturing (128)
MASH (36)
Medical device (4850)
Medtech (4852)
Mergers & acquisitions (6313)
Metabolic disorders (375)
Multiple sclerosis (45)
NASH (11)
Neurodegenerative disease (45)
Neuropsychiatric disorders (16)
Neuroscience (782)
NextGen: Class of 2025 (2070)
Non-profit (1529)
Northern California (1309)
Now hiring (23)
Obesity (210)
Opinion (69)
Ovarian cancer (32)
Pain (42)
Pancreatic cancer (46)
Parkinson's disease (73)
Partnered (7)
Patents (80)
Patient recruitment (38)
Peanut (27)
People (8344)
Pharmaceutical (11)
Pharmacy benefit managers (3)
Phase I (7945)
Phase II (12827)
Phase III (11436)
Pipeline (796)
Podcasts (9)
Policy (32)
Postmarket research (1211)
Preclinical (2646)
Press Release (15)
Prostate cancer (61)
Psychedelics (16)
Radiopharmaceuticals (97)
Rare diseases (173)
Real estate (1324)
Recruiting (19)
Regulatory (7641)
Reports (20)
Research institute (778)
Resumes & cover letters (207)
Rett syndrome (3)
RNA editing (1)
RSV (25)
Schizophrenia (41)
Series A (64)
Series B (43)
Service/supplier (3)
Sickle cell disease (27)
Southern California (1127)
Special edition (8)
Spinal muscular atrophy (82)
Sponsored (10)
Startups (1136)
State (1)
Stomach cancer (5)
Supply chain (37)
The Weekly (8)
United States (10908)
Vaccines (334)
Venture capitalists (19)
Webinars (2)
Weight loss (147)
Women's health (9)
Worklife (7)
Date
Today (145)
Last 7 days (450)
Last 30 days (1700)
Last 365 days (17795)
2025 (4852)
2024 (16897)
2023 (16187)
2022 (20646)
2021 (20272)
2020 (19028)
2019 (16794)
2018 (12749)
2017 (11970)
2016 (10566)
2015 (12716)
2014 (9228)
2013 (7262)
2012 (7941)
2011 (8061)
2010 (7267)
Location
Africa (317)
Alabama (17)
Alaska (2)
Arizona (56)
Arkansas (5)
Asia (15249)
Australia (2340)
California (3005)
Canada (960)
China (270)
Colorado (133)
Connecticut (184)
Delaware (102)
Europe (33774)
Florida (384)
Georgia (92)
Idaho (14)
Illinois (238)
India (8)
Indiana (154)
Iowa (3)
Japan (101)
Kansas (40)
Kentucky (6)
Louisiana (4)
Maine (40)
Maryland (372)
Massachusetts (2182)
Michigan (74)
Minnesota (140)
Mississippi (2)
Missouri (41)
Montana (8)
Nebraska (4)
Nevada (24)
New Hampshire (25)
New Jersey (899)
New Mexico (8)
New York (842)
North Carolina (390)
North Dakota (2)
Northern California (1309)
Ohio (70)
Oklahoma (4)
Oregon (12)
Pennsylvania (596)
Puerto Rico (4)
Rhode Island (7)
South America (465)
South Carolina (7)
Southern California (1127)
Tennessee (41)
Texas (473)
Utah (71)
Virginia (72)
Washington D.C. (25)
Washington State (308)
West Virginia (3)
Wisconsin (42)
235,567 Results for "5".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MicroGenDX Launches “Rapid H5,” a PCR Test for H5 Influenza Detection
March 3, 2025
·
2 min read
Radiopharmaceuticals
5 Big Pharmas Push Boundaries in Radiopharmaceuticals
While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their radiopharmaceutical assets to a market projected to be worth over $13 billion by 2033.
March 31, 2025
·
9 min read
·
Tristan Manalac
Mergers & Acquisitions
Pharma Has Kept M&A Spending Small This Year, With Just One Deal Topping $5B
By far, the largest acquisition of 2024 was Novo Holdings’ yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion. Outside of that, the leading pharmaceutical companies kept to less than $5 billion per deal.
December 11, 2024
·
4 min read
·
Annalee Armstrong
Press Releases
Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery
February 20, 2025
·
3 min read
Press Releases
Insulet Expands Omnipod® 5 to Four More International Markets
March 18, 2025
·
6 min read
Press Releases
CEL-SCI Announces Closing of $2.5 Million Offering
March 18, 2025
·
4 min read
Press Releases
CEL-SCI Announces Pricing of $2.5 Million Offering
March 18, 2025
·
4 min read
Press Releases
Urinary Retention Market Size to Reach USD 5.5 Billion by 2035, Impelled by Rising Prevalence of Urological Disorders
February 14, 2025
·
9 min read
Cell therapy
5 CAR T Cell Therapies With Autoimmune Readouts in 2025
Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune disorders, with several early- to mid-stage readouts expected this year.
March 17, 2025
·
9 min read
·
Tristan Manalac
Deals
Almost 5 Years into $5B Galapagos Partnership, Gilead Execs Start Over With New Spinoff
Five years ago, Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at the original signing.
January 22, 2025
·
5 min read
·
Annalee Armstrong
1 of 23,557
Next
